Concomitant Sjögren’s Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis

Table 1

Baseline demographic and laboratory data.

	PBC(N=226)	PBC/SS(N=56)	P value
Age (years)	52.5(43.0,62.0)	51.5(45.0,58.8)	0.778
Sex, n (%)			0.123
Female	189(83.6)	52(92.9)
Male	37(16.4)	4(7.1)
PLT (× 10^9/L)	127.0(84.0,192.8)	112.0(70.5,171.8)	0.244
INR	1.03(0.97,1.11)	1.01(0.97,1.08)	0.334
Alb (g/L)	41.4(35.1,44.9)	40.2(36.5,43.6)	0.369
Cr (μmol/L)	60.0(52.8,71.0)	62.1(53.5,68.0)	0.635
TB (μmol/L)	19.3(13.4,29.9)	16.1(12.8,25.3)	0.182
ALT (IU/L)	56.5(34.8,82.0)	62.0(40.0,88.5)	0.206
AST (IU/L)	75.0(48.0,110.0)	65.5(44.0,97.0)	0.184
ALP (IU/L)	280.5(159.8,431.3)	274.0(143.0,405.6)	0.233
GGT (IU/L)	257.5(127.8,459.0)	237.0(95.8,421.5)	0.340
Anti-AMA (%)	162(71.7)	39(69.2)	0.619
ANA (%)	210(92.9)	56(100.0)	0.041
IgG (g/L)	16.3(14.2,19.4)	19.3(15.5,22.2)	0.001
IgM (g/L)	3.6(2.3,5.9)	3.7(2.3,5.0)	0.788
Fib-4	3.6(1.9,7.1)	4.2(2.4,8.6)	0.134
APRI,; splenomegaly	1.3(0.7,2.2),; 71(31.4%)	1.7(0.8.2.9),; 19(33.9%)	0.064,; 0.718
Duration of follow-up (months)	21.0(14.0,38.3)	28.0(11.0,65.0)	0.256

Data are expressed as the median (interquartile range); PLT, platelet; INR, international normalized ratio; Alb, albumin; Cr, creatinine; TB, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; anti-AMA, antimitochondrial antibody; ANA, antinuclear antibody; Fib-4, fibrosis score; APRI, aspartate aminotransferase/platelet ratio index; IgG, immunoglobulin G; IgM, immunoglobulin M; SS, Sjögren’s syndrome; and PBC, primary biliary cholangitis.